Imlifidase (Idefirix®) – Desensitisation in kidney transplantation

1. Characteristics

Start date 15.03.2021
Resolution 02.09.2021
Limitation date 03.04.2026
INN Imlifidase
Brand name Idefirix®
Company Hansa Biopharma AB
G-BA procedure ID 2021-03-15-D-647
ATC code L04AA41
ICD-10 codes N18.5Chronic kidney disease, stage 5, Z75.60, Z75.70
Therapeutic area Other diseases ORPHAN
Reason for procedure New INN
Regulatory status Conditional Approval

Indication (German)

Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Subgroup Indication Comparator
Erwachsene Nierentransplantations-Patientinnen und Patienten, die Antikörper besitzen, welche zu einer positiven Kreuzprobe gegen einen verfügbaren verstorbenen Spender führen – (Orphan drug)

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
Imlifidase Idefirix® Desensitisation in kidney transplantation


<< List of all resolutions